Ultima Genomics Selected for Large-Scale Immune Profiling Study with IMU Biosciences and UK Biobank

Source excerpt

Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation --> Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation News provided by Ultima Genomics Oct 19, 2026, 03:05 ET Share this article Share to X Share this article Share to X Photo credit: Ultima Genomics IMU Biosciences and UK Biobank will generate a single-cell immune profiling AI foundational dataset from 80,000 blood samples collected from UK Biobank participants using Ultima Genomics' UG200™ Sequencing Platform and the BD Rhapsody™ Single-Cell Platform from Waters Corporation Ultima's technology continues to support the addition of new omics data layers for UK Biobank and foundational dataset generation for AI following its selection as the sequencing technology for the 600,000-sample UK Biobank Pharma Proteomics Project FREMONT, Calif. , Oct. 19, 2026 /PRNewswire/ -- Ultima Genomics, Inc ., developer of ultra-high-throughput next-generation sequencing (NGS) platforms, today announced that its recently launched UG200 Sequencing Platform has been selected to power a new large-scale immune profiling study with IMU Biosciences and UK Biobank. The study will generate one of the most detailed pictures of the human immune system assembled to date, adding a high-resolution immune data layer and a foundational dataset for AI to UK Biobank, one of the world's most impor

Company press release